New research proposal submissions for the following products, regionally, will be reviewed for consideration of support by Astellas.
Compound | Region/Country |
---|---|
avacincaptad pegol |
|
enfortumab vedotin | |
enzalutamide |
|
gilteritinib | |
fezolinetant |
|
mirabegron |
|
ipragliflozin |
|
roxadustat |
|
tacrolimus |
|
zolbetuximab |
Useful Hyperlinks |
---|
For investigators located in Europe, Israel, Canada: In case your grant application is approved,a contract will be required. |
To view, click on the link below: ISR AREAS OF INTEREST |
For Japan products, please click here: https://www.astellas.com/jp/isr/program/investigator-sponsored-research |
Please do not use this website to report safety information or product complaints. To report safety information or product complaints about an Astellas medicine, please email according to region: For EMEA (Europe, Middle East and Africa): safety-EU@astellas.com ; for Americas (Canada, USA and Latin America): safety-US@astellas.com ; or for Asia/Oceania (Japan, Australasia): safety-JP@astellas.com. |